RxDoctor Payments Data

Mandy Rainey

Nurse Practitioner · Lafayette, LANPI 1144325887

Payments from drug & device makers

$1,096in general payments, 2019–2025

Across 30 payments — averaging $36.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$461
  • Inari Medical, Inc.$189
  • Janssen Products, LP$182
  • Viiv Healthcare Company$138
  • Theratechnologies Inc.$32
  • Boston Scientific$25
  • plus $69 from 5 others

What the payments were for

  • Speaking & faculty fees$161%
  • Food & beverage$89882%
  • Education$18217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,096 in reported general payments places this provider in the 70th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$7,930
Medicare patients
50
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala317$1,273,584
TivicayDolutegravir Sodium209$503,124
EpclusaSofosbuvir/Velpatasvir13$301,691
DescovyEmtricitabine/Tenofov Alafenam129$295,602
TriumeqAbacavir/Dolutegravir/Lamivudi71$253,362
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf43$201,438
Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir15$116,761
VemlidyTenofovir Alafenamide71$104,670
PifeltroDoravirine59$101,279
Darunavir73$78,014
PrezcobixDarunavir/Cobicistat31$76,643
PrezistaDarunavir27$58,425
IsentressRaltegravir Potassium24$44,409
Atovaquone62$32,318
Etravirine22$17,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Epclusa, Descovy, Vemlidy$461$1,975,547530 claims
Viiv Healthcare CompanyTivicay, Triumeq$138$756,486280 claims
Janssen Products, LPSymtuza$182$201,43843 claims
Johnson & JohnsonPrezcobix$9$76,64331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →